Journal article
Association of baseline vitamin D levels with clinical parameters and treatment outcomes in chronic hepatitis B
Journal of hepatology, v 63(5), pp 1086-1092
Nov 2015
PMID: 26143444
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
The relationship between vitamin D levels and chronic hepatitis B (CHB) infection and treatment outcomes are poorly elucidated. We measured pre-treatment serum vitamin D (25-hydroxyvitamin D3; 25[OH]D3) levels and determined their association with clinical parameters and treatment outcomes in active CHB patients without advanced liver disease enrolled in a global clinical trial.
Patients were randomly assigned to either 48weeks of tenofovir disoproxil fumarate (TDF) plus peginterferon alfa-2a (PegIFN), TDF plus PegIFN for 16weeks followed by TDF for 32weeks, PegIFN for 48weeks, or TDF for 120weeks. Univariate and multivariate analyses were conducted to determine associations between vitamin D, baseline factors, and week 48 clinical outcome.
Of 737 patients, 35% had insufficient (⩾20 but <31ng/ml) and 58% had deficient (<20ng/ml) vitamin D levels. In univariate analysis, lower vitamin D levels were significantly associated with the following baseline parameters: younger age, lower uric acid levels, HBeAg-positive status, lower calcium levels, blood draw in winter or autumn, and HBV genotype D. On multivariate analysis, only HBV genotype, season of blood draw, calcium level, and age retained their association. High baseline level of vitamin D was associated with low HBV DNA, normal ALT and HBsAg at week 48 independent of treatment groups, but the association, with the exception of ALT, became statistically insignificant after adjusting for age, gender, HBeAg and HBV genotype.
Abnormally low vitamin D levels are highly prevalent among untreated, active CHB patients. Baseline vitamin D levels are not associated with treatment outcomes, but were associated with normal ALT.
Metrics
Details
- Title
- Association of baseline vitamin D levels with clinical parameters and treatment outcomes in chronic hepatitis B
- Creators
- Henry Lik-Yuen Chan - Chinese University of Hong KongMagdy Elkhashab - Toronto Liver CentreHuy Trinh - San Jose Gastroenterology, San Jose, CA, USAWon Young Tak - Kyungpook National University HospitalXiaoli Ma - Drexel UniversityWan-Long Chuang - Kaohsiung Medical UniversityYoon Jun Kim - Seoul National University Hospital, Seoul, South KoreaEduardo B. Martins - Gilead Sciences, Inc, Foster City, CA, USALanjia Lin - Gilead Sciences, Inc, Foster City, CA, USAPhillip Dinh - Gilead Sciences, Inc, Foster City, CA, USAPrista Charuworn - Gilead Sciences, Inc, Foster City, CA, USAGraham R. Foster - Queen Mary University of LondonPatrick Marcellin - Beaujon Hospital
- Publication Details
- Journal of hepatology, v 63(5), pp 1086-1092
- Publisher
- Elsevier
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- Medicine (Graduate)
- Web of Science ID
- WOS:000363307600007
- Scopus ID
- 2-s2.0-84945447968
- Other Identifier
- 991019167427604721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Collaboration types
- Industry collaboration
- Domestic collaboration
- International collaboration
- Web of Science research areas
- Gastroenterology & Hepatology